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Abstract
Background: Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is a rare inherited mitochondrial fatty acid oxidation disorder associated 
with variations in the ACADS (Acyl-CoA dehydrogenase, C-2 to C-3 short chain) gene. SCADD has highly variable biochemical, genetic and clinical cha-
racteristics. Phenotypes vary from fatal metabolic decompensation to asymptomatic individuals. 
Subject and methods: A Romani boy presented at 3 days after birth with hypoglycaemia, hypotonia and respiratory pauses with brief generalized 
seizures. Afterwards the failure to thrive and developmental delay were present. Organic acids analysis with gas chromatography-mass spectrome-
try (GS/MS) in urine and acylcarnitines analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in dried blood spot were mea-
sured. Deoxyribonucleic acid (DNA) was isolated from blood and polymerase chain reactions (PCRs) were performed for all exons. Sequence analysis 
of all exons and flanking intron sequences of ACADS gene was performed.
Results: Organic acids analysis revealed increased concentration of ethylmalonic acid. Acylcarnitines analysis showed increase of butyrylcarnitine, 
C4-carnitine. C4-carnitine was 3.5 times above the reference range (<0.68 µmol/L). Confirmation analysis for organic acids and acylcarnitine profile 
was performed on the second independent sample and showed the same pattern of increased metabolites. Sequence analysis revealed 3-bp deleti-
on at position 310-312 in homozygous state (c.310_312delGAG). Mutation was previously described as pathogenic in heterozygous state, while it is 
in homozygous state in our patient.
Conclusions: In our case clinical features of a patient, biochemical parameters and genetic data were consistent and showed definitely SCAD defi-
ciency. 
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Short-chain acyl-coenzyme A dehydrogenase de-
ficiency (SCADD) is an autosomal recessive inborn 
error of mitochondrial fatty acid disorder (FAO) (1–
3). Birth prevalence of SCADD from newborn 
screening in California was reported to be 1 in 
34,632 (4). Similar data was reported from the New 
England newborn screening program, approxi-
mately 1 in 33,000 (5). Birth prevalence of SCADD 
with a mutation/variant genotype in the Nether-
lands as high as > 1:1000 was calculated. This is in 
contrast with lower number of patients diagnosed 
clinically (6). 
SCAD is encoded by the ACADS  (Acyl-CoA dehy-
drogenase, C-2 to C-3 short chain) gene, and a 
number of mutations have been associated with 
deficient enzyme activity (7–10). The ACADS gene 
maps to the 12-chromosome (12q24) and spans 14 
kb of genomic deoxyribonucleic acid (DNA), its 1.9 
kb coding region consists of 10 exons (7). SCAD is 
the first enzyme of the mitochondrial short-chain 
β-oxidation spiral catalyzing the dehydrogenation 
of C4 and C6 fatty acids (7). Impaired SCAD activity 
results in accumulation of butyrylcarnitine (C4-car-
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nitine), butyrylglycine, ethylmalonic acid and 
methylsuccinic acid in blood and urine (4). C4-car-
nitine, measured in blood, and ethylmalonic acid, 
measured in urine, are generally used as biochem-
ical markers for SCADD, although accumulation of 
four-carbon carnitine esters, C4-carnitine, occurs 
in two other inherited conditions: isobutyryl-CoA 
dehydrogenase (IBD) deficiency (11) and ethyl-
malonic encephalopathy (12).
The first two cases of SCADD were reported in 
1987 in two neonates who excreted increased con-
centration of urinary ethylmalonate (5). SCADD is a 
heterogeneous condition that has been associat-
ed with various clinical phenotypes ranging from 
fatal metabolic decompensation in infancy to 
asymptomatic individuals (13). Clinical symptoms 
include development delay, hypotonia, epilepsy, 
behavioural disorders and hypoglycaemia (3). 
Most SCADD patients have been diagnosed as a 
result of investigations for neurological symptoms 
and/or hypoglycaemia (1,10,14,15). However, many 
asymptomatic patients have been diagnosed 
through newborn screening programs. 
In this report, we present a first case of SCADD di-
agnosed in Slovenia, with until now the second 
described deletion in ACADS gene. Genetic analy-
sis is in accordance with biochemical findings and 
clinical picture of the described patient.
Patient and methods
Case history
The Romani child was born to no consanguineous 
parents after uneventful pregnancy by spontane-
ous delivery at 36 weeks of gestation with birth 
weight of 2550 g (25-50th percentile), birth length 
46 cm (10-50th percentile), head circumference 33 
cm (50th percentile) and Apgar scores 1 and 5 min-
utes after birth of 9/9, respectively. On the first day 
of life low blood glucose concentration (1.9 
mmol/L) was measured. Parenteral infusion of 10% 
glucose solution was performed to maintain nor-
mal blood glucose concentration. Three days after 
birth hypotonia and respiratory pauses with brief 
generalized seizures occurred. At 4 months of age 
the failure to thrive and moderate developmental 
delay with muscular hypertrophy were noticed. In-
formed consent for genetic testing was obtained 
from parents and all analyses were performed as a 
part of diagnostic procedure according to the 
principles of the Helsinki Declaration.
Materials
Random urine sample without addition of pre-
servative was collected for organic acids analysis, 
creatinine was measured and urine was stored at 
-20 °C prior the analysis. Analysis was done within 
3 days. For the determination of acylcarnitines 
capillary blood was spotted directly on Whatman 
903 filter paper (Whatman GmbH, Dassel, Germa-
ny). Blood samples were allowed to dry at room 
temperature for at least 4 hours. They were stored 
at 8 °C prior the analysis and analysis was done 
within 3 days. Urine samples and dried blood 
spots were collected at 6th day after birth (sam-
pling I) and again at 13th day after birth (sampling 
II). Peripheral venous blood sample for DNA isola-
tion (6 mL) was obtained by venipuncture into 
EDTA tubes (Becton Dickinson, Milan, Italy). 
Biochemical methodology
Creatinine was determined by Jaffe reaction on 
Beckman Coulter AU 400 analyzer (Beckman Coul-
ter, Brea, CA, USA). Qualitative determination of or-
ganic acids was performed on gas chromatogra-
phy–mass spectrometry (GC/MS) system (Agilent 
Technologies, Wilmington, USA). Urine sample was 
oximated with hydroxyl-amine (O-Ethylhydroxy-
lamine hydrochloride, Sigma-Aldrich, Steinheim, 
Germany). An internal standard, 2-phenylbutyric 
acid (Sigma-Aldrich, Steinheim, Germany), was 
added in concentration of 100 mmol/mol creati-
nine. Urine was acidified with HCl (Riedel-de Haën, 
Sigma-Aldrich, Seelze, Germany), saturated with 
NaCl (Sigma-Aldrich, Steinheim, Germany) and or-
ganic acids were extracted using ethyl-acetate 
(Sigma-Aldrich, Steinheim, Germany). Ethyl-ace-
tate layer was separated and evaporated under 
the steam of nitrogen. The dried residue was dis-
solved in pyridine (Sigma-Aldrich, Steinheim, Ger-
many), derivatised with BSTFA (N,O-bis(trimethylsily) 
trifluoroacetamide, Sigma-Aldrich, Steinheim, Ger-
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many) and injected into GC/MS system. Chromato-
graphic conditions were as followed: initial tem-
perature 70 °C, initial time 2 minutes, rate 3.5 °C/
min, final temperature 270 °C, final time 2 minutes. 
The obtained spectra were compared with the 
known library spectra (W8N08 library). 
Determination of acylcarnitines from filter paper 
were performed on tandem mass spectrometer 
3200Q Trap (ABSCIEX, Singapore) with Chromsys-
tems MassChrom Aminoacid and Acylcarnitines 
from dried blood spot commercial reagents kit 
(Grüfelfing, Germany). The sample preparation 
was based on extraction followed by derivatisa-
tion to butyric esters. Positive electro spray ioniza-
tion and multiple reactions monitoring (MRM) 
mode were used. 
Molecular diagnosis
Molecular studies were performed on DNA ex-
tracted from peripheral blood leukocytes using 
FlexiGene isolation kit (Qiagene, Hilden, Germany) 
from patient and his parents. Polymerase chain re-
action (PCR) primers (Eurofins MWG Operon, 
Ebersberg, Germany) were designed on our own 
according to the established laboratory protocol 
(Table 1), covering whole coding regions and in-
tron/exon boundaries of ACADS gene. All PCR re-
actions were performed with GoTaq G2 Flexi DNA 
polymerase (Promega, Madison, USA) using 100 
ng of double stranded DNA, 0.2 mM of each dNT-
Ps (Life Technologies, Carlsbad, USA), 0.32 μM of 
primers, 2 mM of MgCl2 (Promega, Madison, USA), 
1X green buffer (Promega, Madison, USA) and 0.75 
U of polymerase (Promega, Madison, USA) in a fi-
nal reaction volume of 25 μL. The thermo cycling 
procedure consisted of initial denaturing step at 
95°C for 2 min followed by 35 cycles of 94°C for 30 
s, annealing step at 58°C for 30 s, extension step at 
72°C for 30 s  and  final extension at 72°C for 7 min. 
Sequence analysis of all exons and flanking intron 
sequences of ACADS gene was performed using 
3500 genetic analyzer (Applied Biosystem, USA). 
All identified mutations/variants were validated in 
additional independent round of PCR and once 
again sequenced.
Results
Organic acids measurement in the first urine sam-
ple with GC/MS revealed increased concentration 
of ethylmalonic acid. Confirmation analysis for or-
ganic acids from the second urine sample showed 
also slightly increased methylsuccinic acid (qualita-
tive analysis). Butirylglicine was not present (Table 
































ACADS - acyl-CoA dehydrogenase, C-2 to C-3 short chain
Table 1. Sequences of PCR primers for ACADS gene.
Table 2. Qualitative analysis of specific urine metabolites de-
tected in samples of a patient collected on the 6th and 13th day 
of life.
Specific metabolite Sampling I6th day of life
Sampling II
13th day of life
Ethylmalonic acid + ++
Methylsuccinic acid - +
Butyrilglycine - -
++ highly increased ; + slightly increased; - not present
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state. Corydon et al. previously described the mu-
tation as pathogenic in one patient with hypoto-
nia and developmental delay but in heterozygous 
state, the second mutation was not found. Clinical 
signs presented in first week of life as hypotonia 
and developmental delay. Fibroblast SCAD activity 
was undetectable (7). According to the literature, 
molecular effect of specific SCAD variations on cel-
lular function is unclear (1). Since our nucleotide 
variation is 3 bp deletion on both alleles we be-
lieve that it has higher impact on a clinical picture 
than other described mutations in the ACADS 
gene.
We are aware of limitations of this case report. 
There were scarce data on neurological evaluation 
of a patient and enzyme activity has not been 
measured. We also don’t have information about 
parents history related with certain signs and 
symptoms suggestive for SCADD. Additionally, we 
don’t have results for biochemical analyses for par-
ents (organic acids and acylcarnitine analysis).
The disorder has been reported in infants, children 
and adults (7,17). Most symptomatic cases of 
SCADD have been diagnosed due to large diag-
nostic work-up on children with non-specific find-
ings such as development delay, failure to thrive 
and myopathy (18). However, the clinical relevance 
of SCADD is questionable and still under discus-
sion. The reasons are the variability and the nature 
of the symptoms and signs and existence of many 
patients without signs of the disease that are diag-
nosed through newborn screening programs 
(4,14,19). Those patients may remain asymptomatic 
even with the same genotype as symptomatic pa-
tients (13). Moreover, there were alternate explana-
tions for clinical findings when present (4). The re-
ported spectrum of clinical signs is difficult to cor-
relate to enzymatic defect (20-22). Pederson et al. 
propose that SCADD should be considered as a 
disorder of protein folding that can lead to clinical 
disease in combination with other genetic and en-
vironmental factors (1). Also the need to treat af-
fected individuals is unclear. It was shown that 
only patients with history of hypoglycaemia had 
development of hypoglycaemia during fasting 
test (2). Different proteomic studies search for bio-






C4 2.40 0.11-0.68 6th day of life
C4 1.71 0.11-0.68 13th day of life
C4: C4-carnitine, butyrylcarnitine
Table 3. Acylcarnitine analysis in dried blood spots of a patient; 
samples were collected on the 6th and 13th day of life.
showed increase of butyrylcarnitine, C4-carnitine. 
C4-carnitine was 3.5 times above the reference 
range (< 0.68 µmol/L) (Table 3). Acylcarnitine pro-
file was confirmed from the second dried blood 
spot card. Metabolic findings were consistent with 
SCADD. In order to confirm the diagnosis, the DNA 
was isolated from peripheral blood. Sequence anal-
ysis of all exons and flanking intron sequences of 
ACADS gene revealed 3-bp in frame deletion at po-
sition 310-312 in homozygous state (NM_000017.2: 
c.310_312delGAG). The mutation results in the loss 
of glutamine residue at position 104 of the mature 
SCAD protein (p.Glu104del). The sequence variant 
is considered as a mutation according to Mutation-
Taster prediction program (http://www.mutation-
taster.org/). Mutation analysis of parents DNA 
showed the same mutation in heterozygous state. 
Parents are not consanguineous, but they are 
coming from the same community of Romani peo-
ple.
Discussion
We describe a first patient of Romani origin with 
SCADD diagnosed in Slovenia presented with hy-
poglycaemia, hypotonia, seizures, failure to thrive 
and developmental delay. Clinical signs of a pa-
tient were consistent with the most frequent signs, 
reported in the literature (3,4,16). Due to observed 
clinical signs, diagnostic tests for selective screen-
ing of metabolic disorders were done. Increase of 
the biochemical hallmarks, C4-carnitine and ethyl-
malonic acid suggested SCADD. Diagnosis was 
confirmed with mutational analysis and homozy-
gous deletion of 3 nucleotides at position 310-312 
was detected. This mutation was to our knowl-
edge for the first time described in homozygous 
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SCAD deficiency from individuals at risk to devel-
op symptoms (23,24) and genome-wide associa-
tion studies identify genetic variants associated 
with relative levels of C4-carnitine (25).
The described cases of SCADD indicate that thor-
ough workup off all patients with neurological 
signs like development delay, seizures and hypo-
tonia is required. The true relationship between 
this enzyme deficiency and clinical outcomes will 
be determined only by long-term follow-up data 
on SCADD patients diagnosed by selective screen-
ing and those diagnosed by newborn screening. 
In our case clinical picture of a patient, biochemi-
cal parameters and genetic data were concordant 
and showed definitely SCAD deficiency. We hope 
that this will contribute to the better understand-
ing of this disease.
Potential conflict of interest
None declared.
References
 1. Pedersen CB, Kølvraa S, Kølvraa A, Stenbroen V, Kjeldsen 
M, Ensenauer R, et al. The ACADS gene variation spectrum 
in 114 patients with short-chain acyl-CoA dehydrogenase 
(SCAD) deficiency is dominated by missense variations lea-
ding to protein misfolding at the cellular level. Hum Genet 
2008;124:43–56. http://dx.doi.org/10.1007/s00439-008-
0521-9.
 2. Van Maldegem BT, Duran M, Wanders RJA, Waterham HR, 
de Koning TJ, Rubio E, et al. Fasting and fat-loading te-
sts provide pathophysiological insight into short-cha-
in acyl-coenzyme a dehydrogenase deficiency. J Pe-
diatr 2010;156:121–7. http://dx.doi.org/10.1016/j.
jpeds.2009.07.008.
 3. Van Maldegem BT, Wanders RJA, Wijburg FA. Clinical as-
pects of short-chain acyl-CoA dehydrogenase defici-
ency. J Inherit Metab Dis 2010;33:507–11. http://dx.doi.
org/10.1007/s10545-010-9080-z.
 4. Gallant NM, Leydiker K, Tang H, Feuchtbaum L, Lorey F, 
Puckett R, et al. Biochemical, molecular, and clinical cha-
racteristics of children with short chain acyl-CoA dehydro-
genase deficiency detected by newborn screening in Cali-
fornia. Mol Genet Metab 2012;106:55–61. http://dx.doi.
org/10.1016/j.ymgme.2012.02.007.
 5. Amendt BA, Greene C, Sweetman L, Cloherty J, Shih V, 
Moon A, et al. Short-chain acyl-coenzyme A dehydro-
genase deficiency. Clinical and biochemical studies in 
two patients. J Clin Invest 1987;79:1303–9. http://dx.doi.
org/10.1172/JCI112953.
 6. Van Maldegem BT, Kloosterman SF, Janssen WJ, Augustijn 
PB, van der Lee JH, Ijlst L, et al. High prevalence of short-
chain acyl-CoA dehyydrogenase deficiency in the Nether-
lands, but no association with epilepsy of unknown origin 
in childhood. Neuropediatrics 2011;42:13-7. http://dx.doi.
org/10.1055/s-0031-1275342.
 7. Corydon MJ, Vockley J, Rinaldo P, Rhead WJ, Kjeldsen M, 
Winter V, et al. Role of common gene variations in the mo-
lecular pathogenesis of short-chain acyl-CoA dehydroge-
nase deficiency. Pediatr Res 2001;49:18–23. http://dx.doi.
org/10.1203/00006450-200101000-00008.
 8. Bok LA, Vreken P, Wijburg FA, Wanders RJA, Gregersen N, 
Corydon MJ, et al. Short-chain Acyl-CoA dehydrogena-
se deficiency: studies in a large family adding to the com-
plexity of the disorder. Pediatrics 2003;112:1152–5. http://
dx.doi.org/10.1542/peds.112.5.1152.
 9. Pedersen CB, Bross P, Winter VS, Corydon TJ, Bolund L, Bar-
tlett K, et al. Misfolding, degradation, and aggregation 
of variant proteins. The molecular pathogenesis of short 
chain acyl-CoA dehydrogenase (SCAD) deficiency. J Biol 
Chem 2003;278:47449–58. http://dx.doi.org/10.1074/jbc.
M309514200.
10. Tein I, Elpeleg O, Ben-Zeev B, Korman SH, Lossos A, Lev D, 
et al. Short-chain acyl-CoA dehydrogenase gene mutati-
on (c.319C>T) presents with clinical heterogeneity and is 
candidate founder mutation in individuals of Ashkena-
zi Jewish origin. Mol Genet Metab 2008;93:179–89. http://
dx.doi.org/10.1016/j.ymgme.2007.09.021.
11. Pena L, Angle B, Burton B, Charrow J. Follow-up of pa-
tients with short-chain acyl-CoA dehydrogenase and 
isobutyryl-CoA dehydrogenase deficiencies identified thro-
ugh newborn screening: one center’s experience. Genet 
Med Off J Am Coll Med Genet 2012;14:342–7. http://dx.doi.
org/10.1038/gim.2011.9.
12. Barth M, Ottolenghi C, Hubert L, Chrétien D, Serre V, Go-
bin S, et al. Multiple sources of metabolic disturbance in ET-
HE1-related ethylmalonic encephalopathy. J Inherit Metab 
Dis 2010;33:S443–53. http://dx.doi.org/10.1007/s10545-
010-9227-y.
13. Kim SH, Park HD, Sohn YB, Park SW, Cho SY, Ji S, et al. Mu-
tations of ACADS gene associated with short-chain acyl-
coenzyme A dehydrogenase deficiency. Ann Clin Lab Sci 
2011;41:84–8. 
14. Waisbren SE, Levy HL, Noble M, Matern D, Gregersen N, Pa-
sley K, et al. Short-chain acyl-CoA dehydrogenase (SCAD) 
deficiency: an examination of the medical and neurode-
velopmental characteristics of 14 cases identified thro-
ugh newborn screening or clinical symptoms. Mol Ge-
net Metab 2008;95:39–45. http://dx.doi.org/10.1016/j.
ymgme.2008.06.002.
Biochemia Medica 2015;25(2):279–84  http://dx.doi.org/10.11613/BM.2015.029 
284
Repic Lampret B. et al. SCAD deficiency – Case report
15. Van Maldegem BT, Waterham HR, Duran M, van der Vlies M, 
van Woerden CS, Bobu LL, et al. The 625G>A SCAD gene vari-
ant is common but not associated with increased C4-carniti-
ne in newborn blood spots. J Inherit Metab Dis 2005;28:557–
62. http://dx.doi.org/10.1007/s10545-005-0557-0.
16. Jethva R, Bennett MJ, Vockley J. Short-chain acyl-coenzyme 
A dehydrogenase deficiency. Mol Genet Metab 2008;95:195–
200. http://dx.doi.org/10.1016/j.ymgme.2008.09.007.
17. Bhala A, Willi SM, Rinaldo P, Bennett MJ, Schmidt-Sommer-
feld E, Hale DE. Clinical and biochemical characterizati-
on of short-chain acyl-coenzyme A dehydrogenase defici-
ency. J Pediatr 1995;126:910–5. http://dx.doi.org/10.1016/
S0022-3476(95)70207-5.
18. Reddy GS, Sujatha M. A Rare Case of Short-Chain Acyl-COA 
Dehydrogenase Deficiency: The Apparent Rarity of the Dis-
order Results in Under Diagnosis. Indian J Clin Biochem 
IJCB 2011;26:312–5. http://dx.doi.org/10.1007/s12291-
011-0139-x.
19. Cajaiba MM, Hughes AMS, Pierson CR. Central nervous 
system pathology in an infant with short-chain acyl-CoA 
dehydrogenase deficiency (SCADD): evidence for abnormal 
neuronal migration as part of its phenotypic spectrum. Clin 
Neuropathol 2012;31:386–8. http://dx.doi.org/10.5414/
NP300473.
20. Gregersen N, Andresen BS, Bross P. Prevalent mutation in 
fatty acid oxidation disorders: diagnostic considerations. 
Eur J Pediatr 2000;159:S213-18. http://dx.doi.org/10.1007/
PL00014406.
21. Gregersen N, Bross P, Andresen BS. Genetic defects in fatty 
acid beta-oxidation and acyl-CoA dehydrogenases. Eur 
J Biochem 2004;271:470-82. http://dx.doi.org/10.1046/
j.1432-1033.2003.03949.x.
22. Van Maldegem BT, Duran M, Wanders RJ, Niezen-Koning 
KE, Hogeveen M, Ijlst L, et al. Clinical, biochemical, and 
genetic heterogeneity in short-shain acyl-coenzyme A 
dehydrogenase deficiency. JAMA 2006;296:943-52. http://
dx.doi.org/10.1001/jama.296.8.943.
23. Wang W, Mohsen AW, Uechi G, Schreiber E, Balasubrama-
ni M, Day B, et al. Complex changes in the liver mitochon-
drial proteome of short chain acyl-CoA dehydrogenase de-
ficient mice. Mol Gen Metab 2014;112:30-9. http://dx.doi.
org/10.1016/j.ymgme.2014.02.014.
24. Edhager AV, Stenbroen V, Nielsen NS, Bross P, Olsen RK, 
Gregersen N, et al. Proteomic investigation of cultiva-
ted fibroblasts from patients with mitochondrial short-
chain acyl-CoA dehydrogenase deficiency. Mol Ge-
net Metab 2014;111:360-8. http://dx.doi.org/10.1016/j.
ymgme.2014.01.007.
25. Ryckman KK, Smith CJ, Jelliffe-Pawlowski LL, Momany AM, 
Berberich SL, Murray JC. Metabolic heritability at birth: 
implications for chronic disease research. Hum Genet 
2014;133:1049-57. http://dx.doi.org/10.1007/s00439-014-
1450-4.
